Flag Flag Flag Flag
AbbildungAbbildung

News


[1 - 15] [16 - 30] [31 - 34]

The second study of Yestimun® The second study of Yestimun®
The prestigious „European Journal of Nutrition“ just published the second study of Yestimun®: “Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body’s defence against pathogens“. This trial repeated the significant results on the reduction of viral cold infections and reached a striking effect-size of 25%.

The effect of Yestimun® has been proven in both studies within the healthy general population. Therefore our research is in line with the regulation EC 1924/2008 on permitted health-claims. The publication can be downloaded freely here.

Together both studies underline the robustness of the effect of Yestimun® for the improvement in the body’s defence against pathogens.

Please contact us if you want to learn more about Yestimun® and possible applications if dietary supplement or functional food.

Contact:
Eike Hagemann
Tel: +49 (0) 5461-9303-37
e.hagemann@leibergmbh.de

Yestimun® study published Yestimun® study published
The peer-review journal „Food and Nutrition Science“ published the first big scale intervention study of Yestimun® in their June issue. The present study demonstrates a prophylactic effect of yeast beta-glucan on the occurrence of common colds as opposed to placebo. In addition, when these episodes occurred, they were from the beginning less pronounced and subsided faster.

The study design is in contrast to traditional “proof of efficacy” concepts as all significant results in the present study have been shown in the healthy general population. Therefore this study is full in line with the regulation EU No 1924/2006 on nutrition and health-claims of food.

The acquired study-design was the first one to get an EFSA approval for immune health-claims and gathered a great deal of attention among experts. An additional new study now repeats the significant results over the whole study period, now included in the new health-claim application for Yestimun®. This publication also discusses some actual decisions of the EFSA and compares the effect-size with known immune-ingredients like zinc, ascorbic acid and Echinaceae.

Please contact us if you want to learn more about the current publication.

Contact:
Eike Hagemann
Tel: +49 (0) 5461-9303-37
e.hagemann@leibergmbh.de


[1 - 15] [16 - 30] [31 - 34]